**Background**
Heat shock protein 90 (Hsp90) is a highly conserved molecular chaperone that plays a critical role in maintaining the stability and function of numerous client proteins, many of which are oncogenic kinases and transcription factors. Due to its ability to facilitate the folding and maturation of proteins essential for cell survival and proliferation, Hsp90 is frequently overexpressed in various malignancies. Inhibiting Hsp90 leads to the degradation of these client proteins, thereby suppressing tumor growth and inducing apoptosis. Consequently, Hsp90 has become a primary therapeutic target in the development of anticancer strategies. In this context, we will introduce an Hsp90 C-terminal inhibitor – HSP90-IN-22.
**Definition**
HSP90-IN-22 (Compound 35) is a potent Hsp90 inhibitor that exhibits significant antiproliferative properties against human breast cancer cell lines.
**In Vitro Studies**
Regarding the HSP90-IN-22 description, this compound is a 6-acylamino-2-aminoquinoline derivative with a molecular weight of 434.53 and the chemical formula C25H30N4O3. In terms of HSP90-IN-22 biological activity, the compound has been evaluated for its cytotoxicity using MTT assays. In vitro studies demonstrated that HSP90-IN-22 possesses potent antiproliferative activity against human breast cancer cells after 72 hours of incubation. Specifically, it exhibited IC50 values of 3.65 μM for MCF7 breast cancer cells and 2.71 μM for SKBr3 breast cancer cells. These results indicate that the compound effectively inhibits the proliferation of different breast cancer subtypes by targeting the Hsp90 pathway. In conclusion, HSP90-IN-22 is a novel Hsp90 C-terminal inhibitor with promising potential for breast cancer research.
Keywords
HSP90-IN-22, 442898-75-1, HSP, Heat shock proteins, MCF7 cells, SKBr3 cells, antiproliferative, Hsp90, Inhibitor, inhibitor, inhibit
References